- Home
- ACXP vs NTIP Comparison
ACXP vs NTIP Comparison
Compare ACXP & NTIP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACXP
- NTIP
- Stock Information
- Founded
- ACXP 2017
- NTIP 1990
- Country
- ACXP United States
- NTIP United States
- Employees
- ACXP N/A
- NTIP N/A
- Industry
- ACXP Biotechnology: Pharmaceutical Preparations
- NTIP Multi-Sector Companies
- Sector
- ACXP Health Care
- NTIP Miscellaneous
- Exchange
- ACXP Nasdaq
- NTIP Nasdaq
- Market Cap
- ACXP 31.4M
- NTIP 32.9M
- IPO Year
- ACXP 2021
- NTIP 1998
- Fundamental
- Price
- ACXP $0.88
- NTIP $1.38
- Analyst Decision
- ACXP Strong Buy
- NTIP
- Analyst Count
- ACXP 1
- NTIP 0
- Target Price
- ACXP $12.00
- NTIP N/A
- AVG Volume (30 Days)
- ACXP 455.1K
- NTIP 62.9K
- Earning Date
- ACXP 03-14-2025
- NTIP 03-07-2025
- Dividend Yield
- ACXP N/A
- NTIP 7.25%
- EPS Growth
- ACXP N/A
- NTIP N/A
- EPS
- ACXP N/A
- NTIP N/A
- Revenue
- ACXP N/A
- NTIP $1,881,000.00
- Revenue This Year
- ACXP N/A
- NTIP N/A
- Revenue Next Year
- ACXP N/A
- NTIP N/A
- P/E Ratio
- ACXP N/A
- NTIP N/A
- Revenue Growth
- ACXP N/A
- NTIP 129.39
- 52 Week Low
- ACXP $0.68
- NTIP $1.22
- 52 Week High
- ACXP $4.15
- NTIP $2.25
- Technical
- Relative Strength Index (RSI)
- ACXP 49.25
- NTIP 51.53
- Support Level
- ACXP $0.68
- NTIP $1.33
- Resistance Level
- ACXP $1.25
- NTIP $1.47
- Average True Range (ATR)
- ACXP 0.10
- NTIP 0.07
- MACD
- ACXP 0.02
- NTIP -0.00
- Stochastic Oscillator
- ACXP 35.61
- NTIP 43.75
About ACXP Acurx Pharmaceuticals Inc.
Acurx Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention and Food and Drug Administration.
About NTIP Network-1 Technologies Inc.
Network-1 Technologies Inc is involved in the business of the development, licensing, and protection of intellectual property rights. The company's current plan includes continuing to pursue licensing opportunities for its intellectual property assets.